Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

To provide another way for shoppers to get the medications they require in the most convenient fashion, Walgreens has grown its same-day prescription delivery service. The offering is currently available in almost every store location all days of the week, according to a Thursday (July 8) announcement.

Walgreens Brings Same-Day Medication Delivery To Nearly All Stores

Walgreens same-day prescription delivery expanded to nearly all U.S. stores

DEERFIELD, Ill. & CHICAGO--(BUSINESS WIRE)--Walgreens and VillageMD announce plans to open 29 new Village Medical at Walgreens practices in Houston, Austin and El Paso this year.

Walgreens and VillageMD to Open 29 Full-Service Primary Care Practices in Texas This Year

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens announced today expansion of same day prescription delivery* as another way for customers to get the medications they need when, where and how it is most convenient to them. The service is now available in nearly all store locations seven days a week. “Same day prescription delivery is one more way Walgreens is empowering patients to easily and conveniently manage their health,” said John Standley, president, Walgreens. “We are pleased to make this se

Walgreens Expands Same Day Prescription Delivery

AbbVie

Amgen

Amazon

Alibaba

Gilead Sciences

General Mills

Alphabet

Henkel AG & Co KGaA

Reckitt Benckiser Group PLC

Tencent Holdings Limited

The stock market is overvalued, but we can still try to find investments without overpaying. A first category of stocks are recession-proof and undervalued companies like Walgreens Boots Alliance, Henkel, Amgen or AbbVie.

10 Picks For July

CVS Health

Herbalife

3 Retail Pharmacy and Drugstore Stocks to Watch Amid Pandemic Woes

The stock price of Walgreens has seen a 6.5% fall over the last five trading days, while it was down 7.4% in a single trading session yesterday. The company yesterday reported upbeat fiscal Q3 results and raised its outlook for the full year.

Walgreens Stock Is Likely To See Higher Levels After A 7% Drop Yesterday

The future success of Walgreens will maintain pharmacy as key to more foot traffic into stores but weave in technology as critical to the turnaround of this iconic drugstore chain.

New Walgreens CEO Sees ‘Tech Enabled Healthcare' In Future

Walgreens reported a great Q3 with GAAP EPS of $1.27 and revenue of $34.03 billion.

Walgreens - An Unwarranted Dip

Altimmune

Johnson & Johnson

Wall Street crossed over into the second half of the year, as well as a new month and quarter this week, and the transition was a seamless one.

Wall Street Heads Into H2 With Stocks on a Streak

The third-quarter report from Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Thursday surpassed Wall Street expectations, with an EPS beat of 19% and reported revenue of $34 billion, $500 million higher than expectations, according to a Raymond James analyst.  The Walgreens Analysts: Raymond James analyst John Ransom reiterated a Neutral rating.

2 Walgreens Analysts On Why They're Sidelined After Q3 Earnings

Block

CrowdStrike

Regeneron Pharmaceuticals

Square, Regeneron, Walgreen and CrowdStrike were our top stock trades for Friday. Let's get a look at how the charts are setting up now.

4 Top Stock Trades for Friday: SQ, REGN, WBA, CRWD

Chevron

Global oil markets continue to improve, lifting Chevron's prospects, while Walgreens' guidance for upcoming quarters had investors selling.

Dow Jones Adds 79 Points as Chevron Rises on Oil Price Surge, Walgreens Falls on Earnings

Walgreens Boots Alliance, Inc. (WBA) CEO Rosalind Brewer on Q3 2021 Results - Earnings Call Transcript

Micron Technology

Find out why earnings disappointment played a factor with these companies.

These 2 Nasdaq Giants Weighed on Stock Markets Thursday

Walgreens Boots Alliance Inc. (NASDAQ: WBA) published its earnings report for the fiscal third quarter on Thursday that topped analysts' estimates for earnings and revenue. Shares of the company still slid about 7% on Thursday morning.

Analyst: this is why Walgreens stock slid on Thursday despite market-beating results

As people get out again, the drugstore chain said they are refreshing their makeup bags and ordering passport photos.

Walgreens said it's seeing a comeback in discretionary spending. Here are three areas driving growth

Walgreens Boots (WBA) revenues improve 12.1% year-over-year in the third quarter on robust growth in the International and United States segments.

Walgreens Boots (WBA) Q3 Earnings Top Estimates, 2021 View Up

For Walgreens, the rollout of its sweeping COVID-19 vaccine program this year was a demonstration of the company's ability to move quickly and at scale as it accelerates the transformation and restructuring of its pharmacy and retail businesses. Walgreens, the second-largest drug store chain in the U.S. behind CVS, has been focused on reinventing its […]

Walgreens Sees Increased Sales As Personalization Effort Continues

Walgreens administered 25M COVID-19 vaccines and tells investors the pace will slow in the coming weeks and months.

Walgreens administered 25M COVID-19 vaccines, sees pace slowing

Walgreens Boots Alliance Inc (NASDAQ: WBA) reported Q3 earnings of $1.38, beating the consensus estimate of $1.17. Revenue increased 12.1% Y/Y to $34.0 billion, slightly ahead of the consensus of $33.76 billion.

Walgreens Boots Alliance Q3 Earnings Beat Expectations As Vaccinations Boost Prescriptions Business

Despite pointing up in premarket trading, near the bottom of the Dow this morning sits Walgreens Boots Alliance Inc (NASDAQ: WBA), down 7.1% to trade at $48.71 at last check.

Walgreens Stock Pivots Lower Despite Top-Line Beat

Walgreens has administered more than 25 million vaccines against Covid-19, boosting quarterly profits and sales.

Covid Vaccines Boost Walgreens Profits As New CEO Takes Charge

Walgreens Boots Alliance raised its outlook for the year and unveiled its turnaround plans on Thursday, after a stronger than expected fiscal third-quarter.

Walgreens swings to a profit, raises forecast as it looks to accelerate growth under new CEO

Shares of Walgreens Boots Alliance (NASDAQ:WBA) rose 1.5% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 66.27% year over year to $1.38, which beat the estimate of $1.17.

News for Walgreens Stock (WBA)